Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies

被引:73
作者
Steenbergen, Judith N. [1 ]
Mohr, John F. [1 ]
Thorne, Grace M. [1 ]
机构
[1] Cubist Pharmaceut Inc, Lexington, MA 02421 USA
关键词
antimicrobials; gentamicin; rifampicin; vancomycin; RESISTANT STAPHYLOCOCCUS-AUREUS; SIMULATED ENDOCARDIAL VEGETATIONS; GRAM-POSITIVE BACTERIA; PHARMACODYNAMIC MODEL; ENTEROCOCCUS-FAECIUM; REDUCED SUSCEPTIBILITIES; INVITRO ACTIVITY; VANCOMYCIN; GENTAMICIN; RIFAMPIN;
D O I
10.1093/jac/dkp346
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This review summarizes the in vitro and animal model data available on antibiotic combinations with daptomycin. The majority of studies focus on the clinically relevant combinations of daptomycin with rifampicin or with gentamicin. These studies demonstrate that daptomycin does not adversely affect the activity of other antimicrobial agents that may be administered concomitantly. Overall, additive or indifferent effects with daptomycin combinations were observed; however, synergy was observed for certain isolates of vancomycin-resistant enterococci when exposed to daptomycin and rifampicin. Unexpected synergy was demonstrated against methicillin-resistant Staphylococcus aureus by daptomycin and beta-lactams. Most importantly, no in vitro antagonism of daptomycin with any other agent tested was confirmed in these studies. The most striking in vivo effects were noted in two different complicated infection models; i.e. osteomyelitis and implant infections, where rifampicin combinations with daptomycin increased efficacy and reduced the incidence of rifampicin resistance.
引用
收藏
页码:1130 / 1138
页数:9
相关论文
共 31 条
[1]   In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model [J].
Akins, RL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1925-1929
[2]   Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].
Akins, RL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :454-459
[3]   In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin [J].
Anastasiou, Diane M. ;
Thorne, Grace M. ;
Luperchio, Steven A. ;
Alder, Jeff D. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 28 (05) :385-388
[4]  
*ANT AG CHEM, 2006, ANTIMICROB AGENTS CH, V50, P1
[5]   The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].
Arbeit, RD ;
Maki, D ;
Tally, FP ;
Campanaro, E ;
Eisenstein, BI .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681
[6]   Evaluating treatment protocols to prevent antibiotic resistance [J].
Bonhoeffer, S ;
Lipsitch, M ;
Levin, BR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (22) :12106-12111
[7]   Efficacy and Safety Evaluation of Fixed Dose Combination of Cefepime and Amikacin in Comparison with Cefepime Alone in Treatment of Nosocomial Pneumonia Patients [J].
Chaudhary, Manu ;
Shrivastava, Sanjay Mohan ;
Varughese, Lallu ;
Sehgal, Rajesh .
CURRENT CLINICAL PHARMACOLOGY, 2008, 3 (02) :118-122
[8]  
Cilli F, 2006, J CHEMOTHERAPY, V18, P27
[9]   Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology [J].
Credito, Kim ;
Lin, Gengrong ;
Appelbaum, Peter C. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) :1504-1507
[10]   INVITRO ACTIVITY OF LY146032 ALONE AND IN COMBINATION WITH OTHER ANTIBIOTICS AGAINST GRAM-POSITIVE BACTERIA [J].
DEBBIA, E ;
PESCE, A ;
SCHITO, GC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (02) :279-281